Tentative Outline

Special Thematic Issue for Current Drug Targets (CDT)

The Power of Biomarkers to Transform Patients Care in Gynecologic Oncology

Guest Editors: Dr. Khalid El Bairi and Prof. Mariam Amrani

Aims & Scope:

Research on gynecological cancers particularly breast and tubo-ovarian cancers is evolving. Every year, randomized and controlled trials in the area of women’s cancer provide considerable improvements in survival outcomes. Moreover, previously known aggressive gynecological malignancies with poor outcomes are now reconsidered for novel treatments. However, drug resistance is a serious challenge for this significant progress. Predictive and prognostic biomarkers are increasingly used to offer therapeutic decision-making especially with the remarkable advances in targeted therapies in the last decade such as antiangiogenics, poly-ADP-ribose polymerase (PARP) inhibitors and immune-checkpoint blockers. With the emergence of precision medicine, the role of cancer biomarkers is promising as they enable the selection of the best treatment options for the right patients. FDA-approved predictive biomarkers such as BRCA mutational status and tumor-infiltrating lymphocytes (TILs) are enthusiastic examples of successful development of companion diagnostics. In this special issue and as a part of the scientific activities of our recently launched Cancer Biomarkers Working Group, many basic and clinical scientists from different countries were invited to participate in the review writing and share their experiences with this hot topic. Various areas in cancer biomarkers were covered including TILs, genomic signatures, and proteomic markers. Biomarkers that have potential impact for predicting prognosis, survival, and therapy response will be discussed based on recent published data from clinical trials and real-world studies. We strongly believe that our thematic issue will provide clinically actionable information for evidence-based practice in modern cancer management and potential perspectives for further research in gynecologic oncology.

Schedule:

✧ Manuscript submission deadline: July 2019

Contacts:

Guest Editor: Dr. Khalid El Bairi

Affiliation: Cancer Biomarkers Working Group, Mohamed 1st University, Oujda, Morocco

Email: k.elbairi@ump.ac.ma

Any queries should be addressed to cdt@benthamscience.net